Abstract:Licensed natural killer (NK) cells have been demonstrated to have anti-cytomegalovirus (CMV) activity. We prospectively analysed the human leucocyte antigen typing of donor-recipient pairs and the killer cell immunoglobulin-like receptor (KIR) typing of donors for 180 leukaemia patients to assess the predictive roles of licensed NK cells on CMV reactivation post-T-cell-replete haploidentical stem cell transplantation. Multivariate analysis showed that donor-recipient KIR ligand graft-versus-host or host-versus-graft direction mismatch was associated with increased refractory CMV infection (Hazard ratio = 2.556, 95% confidence interval, 1.377-4.744, P = 0.003) post-transplantation. Donor-recipient KIR ligand matching decreased CMV reactivation [51.65% (46.67, 56.62%) vs. 75.28% (70.87, 79.69%), P = 0.012], refractory CMV infection [17.58% (13.77, 21.40%) vs. 35.96% (31.09, 40.82%), P = 0.004] and CMV disease [3.30% (1.51, 5.08%) vs. 11.24% (8.04, 14.43%), P = 0.024] by day 100 post-transplantation. In addition, the percentage of c-interferon expression on donor-derived NK cells was significantly higher in the recipients among the recipient-donor pairs with a KIR ligand match compared with that in the recipients among the pairs with a KIR ligand graft-versus-host or host-versus- graft direction mismatch on days 30 and 100 post-transplantation (P = 0.036 and 0.047, respectively). These findings have suggested that donor-recipient KIR ligand matching might promote the NK cell licensing process, thereby increasing NK cell-mediated protection against CMV reactivation.

Recipient-donor KIR ligand matching prevents CMV reactivation post-haploidentical T cell-replete transplantation